作者
Ola Kleveland, Gabor Kunszt, Marte Bratlie, Thor Ueland, Kaspar Broch, Espen Holte, Annika E Michelsen, Bjørn Bendz, Brage H Amundsen, Terje Espevik, Svend Aakhus, Jan Kristian Damås, Pål Aukrust, Rune Wiseth, Lars Gullestad
发表日期
2016/8/7
期刊
European heart journal
卷号
37
期号
30
页码范围
2406-2413
出版商
Oxford University Press
简介
Aims
Interleukin-6 (IL-6) contributes to atherosclerotic plaque destabilization and is involved in myocardial injury during ischaemia–reperfusion. Interleukin-6 is therefore a potential therapeutic target in myocardial infarction (MI). We hypothesized that the IL-6 receptor antagonist tocilizumab would attenuate inflammation, and secondarily reduce troponin T (TnT) release in non-ST-elevation MI (NSTEMI).
Methods and results
In a two-centre, double-blind, placebo-controlled trial, 117 patients with NSTEMI were randomized at a median of 2 days after symptom onset to receive placebo (n = 59) or tocilizumab (n = 58), administered as a single dose prior to coronary angiography. High sensitivity (hs) C-reactive protein and hsTnT were measured at seven consecutive timepoints between Days 1 and 3. The area under the curve (AUC) for high-sensitivity C-reactive protein was the …
学术搜索中的文章
O Kleveland, G Kunszt, M Bratlie, T Ueland, K Broch… - European heart journal, 2016